Clearside, Aura enter license agreement for suprachoroidal space microinjector

Clearside Biomedical has entered into a worldwide license agreement with Aura Biosciences for the use of Clearside’s suprachoroidal space microinjector, according to a press release.

Aura will use the SCS microinjector to deliver its proprietary drug candidates into the suprachoroidal space for the treatment of ocular cancers, including choroidal melanoma, the release said.

“Clearside is committed to expanding the global reach of our SCS injection platform, and this collaboration with Aura broadens the use of our technology into the ocular oncology space,” George Lasezkay, PharmD, JD, interim CEO and board member of Clearside, said in the release. “Drug delivery to the SCS potentially offers several key advantages compared to intravitreal, periocular or subretinal injections, including repeatable, non-surgical drug administration to the SCS and target tissues in the retina and choroid, avoidance of non-targeted tissues, and strong bioavailability and durability.”

Under the agreement Clearside is eligible to receive payments related to development, regulatory and sales milestones, as well as royalties on product sales that use the microinjector.

Clearside Biomedical has entered into a worldwide license agreement with Aura Biosciences for the use of Clearside’s suprachoroidal space microinjector, according to a press release.

Aura will use the SCS microinjector to deliver its proprietary drug candidates into the suprachoroidal space for the treatment of ocular cancers, including choroidal melanoma, the release said.

“Clearside is committed to expanding the global reach of our SCS injection platform, and this collaboration with Aura broadens the use of our technology into the ocular oncology space,” George Lasezkay, PharmD, JD, interim CEO and board member of Clearside, said in the release. “Drug delivery to the SCS potentially offers several key advantages compared to intravitreal, periocular or subretinal injections, including repeatable, non-surgical drug administration to the SCS and target tissues in the retina and choroid, avoidance of non-targeted tissues, and strong bioavailability and durability.”

Under the agreement Clearside is eligible to receive payments related to development, regulatory and sales milestones, as well as royalties on product sales that use the microinjector.